Apcotex Industries Ltd

- The company is working on CAPEX plans but has not yet shared the quantum of the CAPEX. - The CAPEX will be a combination of debt and internal accruals. - The current debt-equity ratio is around 0.3 and may go up slightly in the short term but not significantly. - No indication of equity fundraising was mentioned in the discussion. - The company plans to announce detailed CAPEX and funding plans in upcoming calls or stock exchange disclosures once finalized.

- The company is working on expansion plans focused on latex products including SBR latex, styrene acrylics, and NBR, with details to be announced soon. - No expansions are planned for Nitrile Latex currently, due to margin concerns. - The upcoming CAPEX will primarily be Brownfield expansions. - CAPEX funding will be through a combination of debt and internal accruals; debt-equity ratio may increase slightly but not substantially (currently 0.3). - Some de-bottlenecking is planned which should be completed by the fiscal year-end. - A small renewable energy investment (wind power SPV) has been made (~3.4 crores), with intentions to invest more long-term to meet rising power needs. - The company aims for ROCE of around 20-25% for new projects; currently, ROCE is around 18% with room for improvement post-capex. - Exact CAPEX quantum and additional volumes/value expected are being finalized and will be communicated soon.

- Company has delivered consistent sales volume growth for 6 straight quarters, with 25% YoY volume growth in Q1 FY’26. - Export revenues grew 37% YoY, contributing to 37% of overall revenue, the highest ever. - Overall revenue expected to reach around Rs. 1,600-1,700 crores in about 3 years, driven by expansions. - Domestic market growth is steady but modest due to high existing market share; growth largely driven by exports. - Expansion plans include debottlenecking and capacity increases focused on latex, SBR latex, styrene acrylics, and NBR. - Specialty product launches in niche applications expected to add future growth potential. - Internal manpower changes and strategic expansions aim to return ApcoBuild (construction segment) to growth by year-end. - Nitrile Latex market share expansion is underway, with re-evaluation of capacity expansion under margin considerations. - Investments will be balanced between organic growth and manageable debt levels.

- Q1 FY26 saw 12% YoY revenue growth and 22% YoY operating EBITDA growth, with improved margin to 10.3%. - Consistent sales volume growth for 6 straight quarters indicates strong operational momentum. - Expansion plans focused on latex, SBR latex, styrene acrylics, and NBR products expected to boost capacity. - Debottlenecking and capacity expansion to continue, with announcements expected soon. - Nitrile Latex volumes growing, but margins currently under pressure due to overcapacity; margin improvements anticipated over next few quarters. - Target long-term EBITDA margins of 14-15% driven by improved Nitrile Latex margins, specialty products, and better operating leverage. - Export growth strong (~40-42% of revenue), providing diversification and growth opportunities. - Sustainable growth expected as domestic market grows with some market share gains. - Overall, earnings and EPS growth appear positive, driven by volume growth, margin expansion, and capacity additions, though some uncertainty remains around Nitrile Latex margins.

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for Apcotex Industries Limited. However, some related insights include: - The company is experiencing strong volume growth, with 25% year-on-year volume increase and highest-ever quarterly sales. - Capacity utilization is high across plants (85-90% for latex plants, around 100% for NBR and others), indicating robust order flow. - Plans for de-bottlenecking and capacity expansion are underway and will be announced shortly, suggesting anticipation of continued demand. - Export revenues grew by 37% year-on-year, making up 37% of total revenue, supported by new product approvals and market expansion. No specific quantitative data about the current order book or pending orders is disclosed in this transcript.